famotidine has been researched along with Carcinoma, Colloid in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Excerpt | Relevance | Reference |
---|---|---|
"Thirty patients with breast cancer were prospectively randomized into case and control groups receiving 40 mg famotidine preoperatively for 10-14 days and routine premedication, respectively." | 9.10 | Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. ( Chattopadhyaya, TK; Gupta, SD; Kapoor, S; Kumar, A; Parshad, R, 2002) |
"Thirty patients with breast cancer were prospectively randomized into case and control groups receiving 40 mg famotidine preoperatively for 10-14 days and routine premedication, respectively." | 5.10 | Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. ( Chattopadhyaya, TK; Gupta, SD; Kapoor, S; Kumar, A; Parshad, R, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Parshad, R | 1 |
Kapoor, S | 1 |
Gupta, SD | 1 |
Kumar, A | 1 |
Chattopadhyaya, TK | 1 |
1 trial available for famotidine and Carcinoma, Colloid
Article | Year |
---|---|
Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Breast Neoplasms; Carcinoma, Lobular; Case-Control Studies; F | 2002 |